CureVac, a clinical-stage biopharmaceutical company pioneering the field of mRNA-based technology, today announced that the European Commission has appointed CureVac’s CEO, Ingmar Hoerr, Ph.D., as one of 15 members of the new High Level Group that will advise the Commission on how to strengthen support for breakthrough, market-creating innovation in Horizon 2020 and future research and innovation programs.

The High Level Group of Innovators brings together leading personalities from across Europe with a wide range of expertise in business innovation, including entrepreneurs, CEOs, investors and other major players in the innovation ecosystem.

Ingmar Hoerr, Ph.D., co-founder and CEO of CureVac, stated: “It is a tremendous honor to be selected by the European Commission as member of the High Level Group focused on advancing innovation throughout the European Union. As one of the pioneering companies in mRNA therapeutics, CureVac is at the forefront of medical innovation, and I am delighted that our experience and leadership will benefit the next generation of European entrepreneurs who are seeking to improve the world through science.”